[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [JAK inhibitors](https://durgical.com/en/pharmacology/classes/jak-inhibitors/) › Ruxolitinib

[Pharmacology](https://durgical.com/en/pharmacology/) · [JAK inhibitors](https://durgical.com/en/pharmacology/classes/jak-inhibitors/)

# Ruxolitinib

An oral JAK1/JAK2 inhibitor for myelofibrosis, polycythaemia vera and graft-versus-host disease. Blood counts and infections are watched.

Updated 2026-11-01

- Class: [JAK inhibitors](https://durgical.com/en/pharmacology/classes/jak-inhibitors/)
- Enzyme: Janus kinases JAK1 and JAK2
- ATC code: L01EJ01

✂**Janus kinases JAK1 and JAK2**Ruxolitinib

ⓘ The figure shows the human JAK2 kinase domain with ruxolitinib in its ATP site.

**Target in 3D:** Janus kinases JAK1 and JAK2. PDB structure 6VGL (RCSB PDB, public domain). [View the structure at RCSB PDB](https://www.rcsb.org/structure/6VGL) · Drag to rotate · pinch to zoom

## Mechanism of action

In myeloproliferative neoplasms the JAK-STAT pathway is overactive, often because of an activating JAK2 mutation. Ruxolitinib inhibits JAK1 and JAK2, which reduces the uncontrolled growth of marrow cells, shrinks the spleen and eases symptoms driven by inflammatory cytokines. In graft-versus-host disease it damps the donor T-cell attack.

- Binds the ATP site of JAK1 and JAK2
- Overactive JAK-STAT signalling falls
- Less marrow overgrowth; smaller spleen
- Fewer cytokine symptoms; calmer GVHD

## Pharmacokinetics

**Absorption**
Oral

**Metabolism**
Liver, mainly by CYP3A4

## Indications

- Myelofibrosis [Essential thrombocythaemia and primary myelofibrosis →](https://durgical.com/en/conditions/essential-thrombocythaemia-and-primary-myelofibrosis/)
- Polycythaemia vera [Polycythaemia vera →](https://durgical.com/en/conditions/polycythaemia-vera/)
- Acute and chronic graft-versus-host disease [Graft-versus-host disease →](https://durgical.com/en/conditions/graft-versus-host-disease/)

## Adverse effects

### Common

- Anaemia, low platelets and low white cells
- Bruising, dizziness, headache
- Raised cholesterol

### Serious (rare, important)

- Bleeding from low platelets
- Serious infections, including tuberculosis, herpes zoster and progressive multifocal leukoencephalopathy
- Heart attack, stroke and blood clots
- Skin cancer and other cancers

## Contraindications

- Hypersensitivity to ruxolitinib

## Key interactions

**CYP3A4 inhibitors (e.g. ketoconazole)**
Slow its clearance and raise its levels.

**CYP3A4 inducers (rifampicin, St John's wort)**
Lower its exposure.

**Other immunosuppressants**
Added infection risk.

## What is monitored

- Blood count before and during treatment
- Lipids
- Signs of infection, including shingles and new neurological symptoms
- Skin checks

## Administration and safety

- Oral tablet or extended-release tablet, with or without food.
- A cream form exists for skin conditions; it is a different product.

## Nursing care

- Check the blood count before each new course or dose change.
- Teach to report bleeding, unusual bruising, pale skin or tiredness.
- Teach to report a painful one-sided rash, worsening weakness, trouble speaking or memory changes.
- Ask about St John's wort and other herbal products.

## Pregnancy and breastfeeding

Human data are limited; the treating team weighs benefits and risks.

## Memory aid

RUXolitinib RUns the marrow down: JAK2 overdrive in myelofibrosis and polycythaemia — watch the counts.

## Test yourself

Think of the answer, then tap the question to see it.

## Why is JAK2 a target in myeloproliferative neoplasms?

Many carry an activating JAK2 mutation that keeps the JAK-STAT pathway switched on.

## What is the main laboratory toxicity of ruxolitinib?

Low blood counts: anaemia, thrombocytopenia and neutropenia.

## Which transplant complication is treated with ruxolitinib?

Graft-versus-host disease after a stem-cell transplant.

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/ruxolitinib/)

## Related drugs

- [Baricitinib](https://durgical.com/en/pharmacology/baricitinib/)
- [Tofacitinib](https://durgical.com/en/pharmacology/tofacitinib/)

## Related conditions

- [Essential thrombocythaemia and primary myelofibrosis](https://durgical.com/en/conditions/essential-thrombocythaemia-and-primary-myelofibrosis/)
- [Polycythaemia vera](https://durgical.com/en/conditions/polycythaemia-vera/)
- [Graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/)

[← Back to the class: JAK inhibitors](https://durgical.com/en/pharmacology/classes/jak-inhibitors/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [Ruxolitinib: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a612006.html) (MedlinePlus (U.S. National Library of Medicine), 2026); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 39 (McGraw Hill, 2023); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=L01EJ01) (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/ruxolitinib/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/ruxolitinib/